OncoMatch/Clinical Trials/NCT05753618
Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy
Is NCT05753618 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Granulocyte Colony-Stimulating Factor (G-CSF) and Omission of Granulocyte Colony-Stimulating Factor (G-CSF) for early-stage breast cancer.
Treatment: Granulocyte Colony-Stimulating Factor (G-CSF) · Omission of Granulocyte Colony-Stimulating Factor (G-CSF) — The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Excluded: Stage IV
early-stage or locally-advanced breast cancer; Metastatic cancer [excluded]
Prior therapy
Cannot have received: cytotoxic chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05753618 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages